Proprietary AI analyst is now available

Profarma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Profarma and similar public comparables like Fangzhou, Green Cross Health, MARX Biotech, d1000 and more.

Profarma Overview

About Profarma

Profarma Distribuidora De Produtos Farmaceuticos SA is a Brazil-based company. It is engaged in wholesale and distribution of pharmaceuticals, cosmetics and similar products, and toiletries. Profarma also holds interests in other companies, regardless of their business sector. The company through its logistics department distributes products in the South, Southeast, Northeast and Center-West regions of Brazil. The firm operates in the pharmaceutical distribution, hospital and specialty, retail segments.


Founded

1961

HQ

Brazil

Employees

6.3K

Sectors

Financials (FY)

Revenue: $2B
EBITDA: $102M

EV

$415M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Profarma Financials

Profarma reported last fiscal year revenue of $2B and EBITDA of $102M.

In the same fiscal year, Profarma generated $345M in gross profit, $102M in EBITDA, and $23M in net income.


Profarma P&L

In the most recent fiscal year, Profarma reported revenue of $2B and EBITDA of $102M.

Profarma is profitable as of last fiscal year, with gross margin of 15%, EBITDA margin of 5%, and net margin of 1%.

See analyst estimates for Profarma
Last FY202320242025202620272028
Revenue$2B$2B$2B$2B
Gross Profit$345M$254M$300M$345M
Gross Margin15%15%15%15%
EBITDA$102M$70M$79M$102M
EBITDA Margin5%4%4%5%
EBIT Margin3%3%3%3%
Net Profit$23M$14M$23M$23M
Net Margin1%1%1%1%
Net Debt$126M---

Financial data powered by Morningstar, Inc.

Profarma Stock Performance

Profarma has current market cap of $162M, and enterprise value of $415M.

Market Cap Evolution


Profarma's stock price is $1.32.

Profarma share price decreased by 5.7% in the last 30 days, and by 23.2% in the last year.

Profarma has an EPS (earnings per share) of $0.19.

See more trading valuation data for Profarma
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$415M$162M-5.2%-5.7%-20.2%-23.2%$0.19

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Profarma Valuation Multiples

Profarma trades at 0.2x EV/Revenue multiple, and 4.1x EV/EBITDA.

See NTM and 2027E valuation multiples for Profarma

Profarma Financial Valuation Multiples

As of June 5, 2026, Profarma has market cap of $162M and EV of $415M.

Profarma has a P/E ratio of 6.9x.

Last FY202320242025202620272028
EV/Revenue0.2x0.2x0.2x0.2x
EV/EBITDA4.1x6.0x5.2x4.1x
EV/EBIT6.0x9.5x8.3x6.0x
EV/Gross Profit1.2x1.6x1.4x1.2x
P/E6.9x11.7x7.2x6.9x
EV/FCF4.9x8.5x4.5x4.9x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Profarma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Profarma Margins & Growth Rates

In the most recent fiscal year, Profarma reported gross margin of 15%, EBITDA margin of 5%, and net margin of 1%.

See estimated margins and future growth rates for Profarma

Profarma Margins

Last FY20242025202720282029
Gross Margin15%15%15%
EBITDA Margin5%4%5%
EBIT Margin3%3%3%
Net Margin1%1%1%
FCF Margin4%5%4%

Profarma Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth17%13%
Gross Profit Growth18%15%
EBITDA Growth14%29%
EBIT Growth14%38%
Net Profit Growth63%4%
FCF Growth90%(8%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Profarma Operational KPIs

Profarma's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.0M for the same period.

Access forward-looking KPIs for Profarma
Last FY202320242025202620272028
Revenue per Employee$0.4M---
Opex per Employee$0.0M---
Opex to Revenue12%12%12%12%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Profarma Competitors

Profarma competitors include Fangzhou, Green Cross Health, MARX Biotech, d1000, BlueMTec, Talea Group, PetMeds, YSB, SC Ropharma and Farmacosmo.

Most Profarma public comparables operate across Pharmacies.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Fangzhou0.2x0.2x25.2x19.8x
Green Cross Health0.8x-7.9x-
MARX Biotech5.0x-34.7x-
d10000.3x-4.1x-
BlueMTec0.5x-79.2x-
Talea Group0.6x-24.4x-
PetMeds0.1x0.1x(0.8x)(0.5x)
YSB0.0x-2.0x-

This data is available for Pro users. Sign up to see all Profarma competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Profarma

When was Profarma founded?Profarma was founded in 1961.
Where is Profarma headquartered?Profarma is headquartered in Brazil.
How many employees does Profarma have?As of today, Profarma has over 6K employees.
Is Profarma publicly listed?Yes, Profarma is a public company listed on B3.
What is the stock symbol of Profarma?Profarma trades under PFRM3 ticker.
When did Profarma go public?Profarma went public in 2006.
Who are competitors of Profarma?Profarma main competitors include Fangzhou, Green Cross Health, MARX Biotech, d1000, BlueMTec, Talea Group, PetMeds, YSB, SC Ropharma, Farmacosmo.
What is the current market cap of Profarma?Profarma's current market cap is $162M.
What is the current revenue of Profarma?Profarma's last fiscal year revenue is $2B.
What is the current EV/Revenue multiple of Profarma?Current revenue multiple of Profarma is 0.2x.
Is Profarma profitable?No, Profarma is not profitable.
How many companies Profarma has acquired to date?Profarma hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Profarma has invested to date?Profarma hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Profarma

Lists including Profarma

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial